Jump to main content
Jump to site search

Issue 39, 2016
Previous Article Next Article

How Zn can impede Cu detoxification by chelating agents in Alzheimer's disease: a proof-of-concept study

Author affiliations

Abstract

The role of Cu and Zn ions in Alzheimer's disease is linked to the consequences of their coordination to the amyloid-β (Aβ) peptide, i.e. to the modulation of Aβ aggregation and to the production of Reactive Oxygen Species (ROS), two central events of the so-called amyloid cascade. The role of both ions in Aβ aggregation is still controversial. Conversely the higher toxicity of the redox competent Cu ions (compared to the redox inert Zn ions) in ROS production is acknowledged. Thus the Cu ions can be considered as the main therapeutic target. Because Zn ions are present in higher quantity than Cu ions in the synaptic cleft, they can prevent detoxification of Cu by chelators unless they have an unusually high Cu over Zn selectivity. We describe a proof-of-concept study where the role of Zn on the metal swap reaction between two prototypical ligands and the Cu(Aβ) species has been investigated by several complementary spectroscopic techniques (UV-Vis, EPR and XANES). The first ligand has a higher Cu over Zn selectivity relative to the one of Aβ peptide while the second one exhibits a classical Cu over Zn selectivity. How Zn impacts the effect of the ligands on Cu-induced ROS production and Aβ aggregation is also reported.

Graphical abstract: How Zn can impede Cu detoxification by chelating agents in Alzheimer's disease: a proof-of-concept study

Back to tab navigation

Supplementary files

Publication details

The article was received on 10 Jun 2016, accepted on 23 Aug 2016 and first published on 31 Aug 2016


Article type: Paper
DOI: 10.1039/C6DT02308H
Author version
available:
Download author version (PDF)
Citation: Dalton Trans., 2016,45, 15671-15678
  • Open access: Creative Commons BY-NC license
  •   Request permissions

    How Zn can impede Cu detoxification by chelating agents in Alzheimer's disease: a proof-of-concept study

    A. Conte-Daban, A. Day, P. Faller and C. Hureau, Dalton Trans., 2016, 45, 15671
    DOI: 10.1039/C6DT02308H

    This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material and it is not used for commercial purposes.

    Reproduced material should be attributed as follows:

    • For reproduction of material from NJC:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC.
    • For reproduction of material from PCCP:
      [Original citation] - Published by the PCCP Owner Societies.
    • For reproduction of material from PPS:
      [Original citation] - Published by The Royal Society of Chemistry (RSC) on behalf of the European Society for Photobiology, the European Photochemistry Association, and RSC.
    • For reproduction of material from all other RSC journals:
      [Original citation] - Published by The Royal Society of Chemistry.

    Information about reproducing material from RSC articles with different licences is available on our Permission Requests page.

Search articles by author

Spotlight

Advertisements